尽管有可能改善临床结果，但许多非小细胞肺癌患者并未接受指南推荐的生物标志物导向治疗。获得及时、准确和全面的分子分析（包括目标蛋白过度表达）对于做出充分知情的治疗决策至关重要。反过来，这需要最佳的组织管理来保护和最大限度地利用这种宝贵的有限资源。在这里，一组领先的胸部病理学家推荐了最佳组织管理需要考虑的因素。从首次怀疑肺癌开始，将预测性生物标志物测试放在首位应该推动适当保存组织以支持分子表征和治疗选择的实践和程序的发展。© 2023 作者。组织病理学由约翰·威利出版

Many patients with non-small cell lung cancer do not receive guideline-recommended, biomarker-directed therapy, despite the potential for improved clinical outcomes. Access to timely, accurate, and comprehensive molecular profiling, including targetable protein overexpression, is essential to allow fully informed treatment decisions to be taken. In turn, this requires optimal tissue management to protect and maximize the use of this precious finite resource. Here, a group of leading thoracic pathologists recommend factors to consider for optimal tissue management. Starting from when lung cancer is first suspected, keeping predictive biomarker testing in the front of the mind should drive the development of practices and procedures that conserve tissue appropriately to support molecular characterization and treatment selection.© 2023 The Authors. Histopathology published by John Wiley & Sons Ltd.